Nutritionist advice on managing side effects highlights growing patient support needs for weight-loss injections and pills
Executive summary: A Handelsblatt article published on September 3, 2026 quotes a nutritionist giving tips to alleviate nausea, bloating, and constipation from weight‑loss injectable and oral therapies. Side‑effect management influences patient adherence and thus the commercial success of GLP‑1‑based obesity treatments, affecting drug makers’ sales and potential reimbursement policies.
Who is involved: Nutritionist (unnamed), patients using semaglutide or tirzepatide‑based products, pharmaceutical companies such as Novo Nordisk and Eli Lilly.
Likely next: Patients may increasingly seek adjunct nutritional counseling, and companies could expand patient‑support programs or update labeling with dietary guidance.
The Handelsblatt article features a nutritionist offering practical dietary advice to alleviate common gastrointestinal side effects—such as nausea, bloating, and constipation—reported with GLP‑1‑based weight‑loss injections and pills. While the piece does not present new clinical trial results or regulatory updates, it underscores how tolerability concerns are becoming a focal point as these medicines expand from diabetes treatment into wider obesity management. The emphasis on symptom management signals a growing patient‑support ecosystem around these therapies. As more individuals use GLP‑1 agents for weight loss, demand for accessible nutrition counseling, tailored meal plans, and digital adherence tools is likely to rise. Pharmaceutical companies may respond by expanding patient‑support programs that combine drug provision with dietitian guidance or partnering with health‑tech platforms to improve tolerability and persistence. In the near term, we could see more collaborations between drug makers, nutrition services, and insurers aimed at reducing discontinuation rates and addressing real‑world effectiveness.
Timeline
- — Ernährungsexpertin gibt Tipps: Abnehmspritze und -pille: Was hilft bei Nebenwirkungen? (Handelsblatt)
Analysis — what this means
Sectors affected
- Pharmaceuticals (GLP-1 receptor agonists)
Key entities
Sources
Open the full interactive case file on Beyond →